AGEN
AgenusAGEN
AGEN
About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Employees: 316
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
575% more call options, than puts
Call options by funds: $398K | Put options by funds: $59K
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 85 [Q4 2024] → 87 (+2) [Q1 2025]
2.46% less ownership
Funds ownership: 35.97% [Q4 2024] → 33.51% (-2.46%) [Q1 2025]
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
45% less capital invested
Capital invested by funds: $23.1M [Q4 2024] → $12.8M (-$10.4M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
28%
upside
Avg. target
$15.50
230%
upside
High target
$25
432%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Baird Colleen Kusy | 28%upside $6 | Neutral Maintained | 4 Jun 2025 |
HC Wainwright & Co. Emily Bodnar | 432%upside $25 | Buy Upgraded | 4 Jun 2025 |
Financial journalist opinion
Based on 7 articles about AGEN published over the past 30 days
Neutral
Business Wire
4 days ago
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy mat.
Positive
Benzinga
1 week ago
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s AGEN U.S.-based biologics CMC facilities.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade
The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
1 week ago
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-t.
Neutral
Business Wire
2 weeks ago
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approxim.
Positive
Seeking Alpha
3 weeks ago
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.
Positive
Zacks Investment Research
3 weeks ago
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
Business Wire
1 month ago
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 12.
Neutral
Seeking Alpha
1 month ago
Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Negative
Zacks Investment Research
1 month ago
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.
Charts implemented using Lightweight Charts™